- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates.
Dr Lal PathLabs' wholly-owned Dubai subsidiary incorporated a new step-down subsidiary, Dr Lal PathLabs Indomed LLC, in Tashkent, Uzbekistan. This expands its diagnostic services, with the subsidiary subscribing to 70% of the new entity's share capital at face value.
Dr. Lal PathLabs delivered a strong Q1 FY27. Revenue soared 19.1% YoY to Rs. 798 Cr, marking the highest quarterly growth in four years, with patient volumes up 8.2%. EBITDA grew 28.7% to Rs. 247 Cr (31% margin), while PAT increased 27.2% to Rs. 170 Cr. An interim dividend of...